Kevin Kalinsky, MD, MS

Articles

Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS

November 7th 2024

Kevin Kalinsky, MD, MS, discusses his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer evolving into the future.

Dr Kalinsky on the Future of Treatment With T-DXd in HER2+ Breast Cancer

November 5th 2024

Kevin Kalinsky, MD, MS, discusses future treatment directions with T-DXd in breast cancer, as well as the evolving role of HER2 classification.

Dr Kalinsky on Unmet Needs and Findings from RxPONDER in HR+/HER2– Breast Cancer

August 15th 2024

Kevin Kalinsky, MD, MS, discusses AMH levels and responses in premenopausal HR+/HER2–, node-positive breast cancer.

Dr Kalinsky on the Utility of the postMONARCH Trial Regimen in HR+/HER2– Breast Cancer

June 14th 2024

Kevin Kalinsky, MD, MS, discusses the utility of the postMONARCH trial regimen in hormone receptor–positive/HER2-negative advanced breast cancer.

Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 3rd 2024

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Ongoing Research and Unmet Needs in Patients With Breast Cancer and ESR1 Mutations

February 6th 2024

Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.

SERENA-2: Camizestrant vs Fulvestrant in Advanced ER+/HER2- Breast Cancer

January 30th 2024

Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.

The Role of Elacestrant in Breast Cancer

January 30th 2024

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

EMERALD: Elacestrant in ER+/HER2- Advanced Breast Cancer

January 23rd 2024

Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.

PADA-1 Trial: ctDNA Monitoring for Acquired ESR1 Mutations in Advanced Breast Cancer

January 23rd 2024

Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).

Overcoming Challenges in Biomarker Testing in Breast Cancer

January 16th 2024

Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.

Testing for ESR1 Mutations in Breast Cancer

January 16th 2024

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape

December 1st 2023

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Educating Community Specialists on Evolving Treatment Landscape

November 24th 2023

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

Future Outlook for Treating Breast and Lung Cancers

November 24th 2023

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

Dr Kalinsky on Remaining Treatment Questions in Breast Cancer

November 17th 2023

Kevin Kalinsky, MD, MS, discusses key takeaways from the 2023 Bridging the Gaps in Breast Cancer meeting, highlighting questions that continue to persist in the treatment of breast cancer.

Future Directions in Gastric Cancer Treatment

November 17th 2023

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Treatment Considerations With TROP2-Targeted Therapy

November 17th 2023

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

TROP2-Targeting Antibody-Drug Conjugates

November 10th 2023

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies

November 10th 2023

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.